On Friday, Sarepta Therapeutics got an upgrade to its Relative Strength (RS) Rating, from 61 to 75.
IBD's unique rating measures price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks often have an RS Rating of at least 80 in the early stages of their moves. See if Sarepta Therapeutics can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
While Sarepta Therapeutics is not near a proper buy zone right now, see if it goes on to form and break out from a proper consolidation.
Earnings grew 100% last quarter, up from 0% in the prior report. Revenue also increased, from 39% to 41%.
Sarepta Therapeutics earns the No. 21 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
